Constantiam Biosciences
Constantiam Biosciences accelerates the development of precision diagnostics and therapeutics by elucidating the consequences of human genetic variation. The company integrates massively multiplexed functional genomics experiments with human biobank data using probabilistic machine learning. Its key products include RareScan, which classifies variants of uncertain significance (VUS) to improve rare disease diagnosis and drug response prediction; Genable, which prioritizes drug targets using human genetic data and machine learning; StratiVar, which optimizes clinical trial enrollment by assessing protein variant susceptibility to therapeutics; and MAVEvidence, a resource for functional evidence in clinical genetics. Constantiam's approach expands patient access to treatments, increases drug development success rates, and supports clinical genetics with comprehensive variant interpretation tools, positioning it as a leader in genomic medicine innovation.
Constantiam Biosciences
Constantiam Biosciences accelerates the development of precision diagnostics and therapeutics by elucidating the consequences of human genetic variation. The company integrates massively multiplexed functional genomics experiments with human biobank data using probabilistic machine learning. Its key products include RareScan, which classifies variants of uncertain significance (VUS) to improve rare disease diagnosis and drug response prediction; Genable, which prioritizes drug targets using human genetic data and machine learning; StratiVar, which optimizes clinical trial enrollment by assessing protein variant susceptibility to therapeutics; and MAVEvidence, a resource for functional evidence in clinical genetics. Constantiam's approach expands patient access to treatments, increases drug development success rates, and supports clinical genetics with comprehensive variant interpretation tools, positioning it as a leader in genomic medicine innovation.